PDCD1 and glioblastoma: In the future, this vector must be studied for its in vivo effects in order to determine its potential as a clinically applicable tool for inducing PD-1-disrupted EvCAR-T cells, and to improve the efficacy of EvCAR-T cell-based adoptive immunotherapy for GBM.